Urinary iodine excretion (UIE) screening in newborn exposed to iodine-containing antiseptic.
Anna Rapa(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), L Zannino, Mauro Zaffaroni(Associazione Italiana Sclerosi Multipla), Enrica Fabbrizi, Pi Torresani, G Bona, Luciano Cavallo(Online Technologies (United States)), Alessandro Salvatoni, Roberto Rusconi(Humanitas University), R. Gallina, Federica Sacco(Sapienza University of Rome), E Chiorboli, Marco Cappa(Bambino Gesù Children's Hospital), Giulia Morganti, Francesca Frisone, L Silvestro, C Corbetta, C. Desanctis, Marco Pezzati, Giuseppe Tonini(Campus Bio Medico University Hospital), Luigi Moschini(Istituti Ospitalieri di Cremona), Lorenzo Pagliano(Politecnico di Milano), Giovanna Weber(Vita-Salute San Raffaele University), Alessandra Cassio(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Livio Gargantini, C Giaretto, Cigolotti Ac, Giuliana Trifirò, G Saggese, A. Spada, Daniela Larizza, A Perona, Rondanini Gf
Hormone Research in Paediatrics
January 1, 1996
Cited by 3
Related Papers
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)
|The Lancet|2002|552
Bacterial transport suppressed by fluid shear
|Nature Physics|2014|425